The author review the characteristics of pharmacokinetics, clinical efficacy and tolerability of oral dosage forms of alpha1-blockers with modified release, used in the treatment of lower urinary tract symptoms in patients with benign prostatic hypertrophy. The following dosage forms are considered: doxazosin GITS, alfuzosin with slow release (Dalfaz retard) and controlled release (Dalfaz CR), tamsulosin with modified release (Omnic) and controlled release (Omnic Okas).

Keywords: alfuzosin, lower urinary tract symptoms, doxazosin, tamsulosin, benign prostatic hypertrophy, hypertension